Technical Articles

KRAS G12C/CRBN

Application of KRAS G12C/CRBN PROTAC Kit Based on TR-FRET Technology in Targeted Protein Degradation Research

2026-04-14

KRAS activating mutations are detectable in 25% to 30% of non-squamous non-small cell lung cancers, representing the most common genetic driver event in this cancer type. The Ras protein family includes three subtypes: KRAS, HRAS, and NRAS, with KRAS mutations accounting for 85% of Ras-driven cancers.

View details

Drug Research
TR-FRET Technology
KRAS G12C/CRBN
Protein Degradation

Total 1

Go to